Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | 1 | — | — | — | 1 |
Prolymphocytic leukemia | D015463 | — | — | — | 1 | — | — | — | 1 |
Lymphoid leukemia | D007945 | — | C91 | — | 1 | — | — | — | 1 |
Drug common name | ALVOCIDIB |
INN | alvocidib |
Description | Alvocidib is a synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation. It has a role as an antineoplastic agent, an EC 2.7.11.22 (cyclin-dependent kinase) inhibitor, an antirheumatic drug and an apoptosis inducer. It is a dihydroxyflavone, a hydroxypiperidine, a member of monochlorobenzenes and a tertiary amino compound. It is a conjugate base of an alvocidib(1+). |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1 |
PDB | — |
CAS-ID | 146426-40-6 |
RxCUI | — |
ChEMBL ID | CHEMBL428690 |
ChEBI ID | — |
PubChem CID | 5287969 |
DrugBank | DB03496 |
UNII ID | 45AD6X575G (ChemIDplus, GSRS) |